Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-33


Brief Information

Target Synonym:Nuclear Factor For High Endothelial Venules,DVS27-Related Protein,IL1F11,IL33,Interleukin-1 family member 11,IL-1F11,Interleukin 33,Nuclear Factor From High Endothelial Venules,C9orf26,NF-HEV,Chromosome 9 Open Reading Frame 26 (NF-HEV),Interleukin-1 Family, Member 11,NFEHEV,DVS27,IL-33,NFHEV,Interleukin-33,DKFZp586H0523
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IL3-H52H7-Cell-based assay

Human IL-33 Protein, His Tag, premium grade (Cat. No. IL3-H52H7) induces IL-8 secretion in HUVECs. The EC50 for this effect is 193.0-311.8 ng/mL (Routinely tested).

 IL-33 BLI

Loaded Human IL-1RL1, Fc Tag (Cat. No. IL1-H5250) on Protein A Biosensor, can bind with Biotinylated Human IL-33, His,Avitag (Cat. No. IL3-H82H5) an affinity constant of 1.81 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

 IL-33 BLI

Loaded Human IL-1RL1, Fc Tag (Cat. No. IL1-H5250) on Protein A Biosensor, can bind with Human IL-33 Protein, His Tag, premium grade (Cat. No. IL3-H52H7) an affinity constant of 1.31 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name



Interleukin 33 (IL33) is known as C9orf26, DKFZp586H0523, DVS27, NF-HEV, NFEHEV, RP11-575C20.2,and is a cytokine belonging to the IL-1 superfamily. IL-33 induces helper T cells, mast cells, eosinophils and basophils to produce type 2 cytokines. IL-33 mediates its biological effects by interacting with the receptors ST2 (aka IL1RL1) and IL-1 Receptor Accessory Protein (IL1RAP), activating intracellular molecules in the NF-κB and MAP kinase signaling pathways that drive production of type 2 cytokines (e.g. IL-5 and IL-13) from polarized Th2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PF-07264660 PF-07264660 Phase 2 Clinical Pfizer Inc Dermatitis, Atopic Details
PF-06817024 PF-06817024 Phase 1 Clinical Pfizer Inc Nose Diseases; Dermatitis, Atopic Details
CAN-10 CAN-10 Phase 1 Clinical Lund University Foundation Scleroderma, Systemic; Psoriasis; Myocarditis; Plaque psoriasis Details
MT-2990 MT-2990 Phase 2 Clinical Mitsubishi Tanabe Pharma Corp Pain; Rhinitis, Allergic, Seasonal; Vasculitis; Endometriosis Details
Tozorakimab MEDI-3506 Phase 3 Clinical Medimmune Pneumonia, Viral; Asthma; Diabetic Nephropathies; Pulmonary Disease, Chronic Obstructive; Bronchitis, Chronic; Dermatitis, Atopic Details
SSGJ-621 SSGJ-621 Phase 1 Clinical Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd Asthma; Pulmonary Disease, Chronic Obstructive Details
Etokimab ANB-020 Phase 2 Clinical Anaptysbio Inc Pulmonary Eosinophilia; Asthma; Sinusitis; Peanut Hypersensitivity; Hypersensitivity; Dermatitis, Atopic Details
Torudokimab LY-3375880 Phase 1 Clinical Eli Lilly And Company Dermatitis, Atopic Details
Itepekimab REGN-3500; SAR-440340 Phase 3 Clinical Regeneron Pharmaceuticals Inc, Sanofi Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message